Bausch Health Companies (BHC) Tax Provisions (2009 - 2026)
Bausch Health Companies (BHC) reported Tax Provisions of $77.0 million for Q1 2026, up 97.44% on a YoY basis from $39.0 million in Q1 2025, and down 51.57% sequentially from $159.0 million in Q4 2025.
Bausch Health Companies (BHC) Tax Provisions (2009 - 2026) Analysis & Trends
Bausch Health Companies (BHC) has 18 years of Tax Provisions data on file, last reported at $77.0 million in Q1 2026.
- For the quarter ending Q1 2026, Tax Provisions rose 97.44% year-over-year to $77.0 million; the trailing twelve-month figure through Mar 2026 stood at $285.0 million (up 5.56% YoY), and the FY2025 full-year result was $247.0 million, up 3.35% from the prior year.
- Tax Provisions eased to $77.0 million in Q1 2026, from $159.0 million in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $159.0 million in Q4 2025 to a low of -$16.0 million in Q1 2022.
- A 5-year average of $51.0 million and a median of $49.0 million in 2024 frame the typical range for Tax Provisions.
- Across the five-year window, Tax Provisions slumped 200.0% in 2022 and surged 556.25% in 2023, its largest moves.
- Tracing BHC's Tax Provisions over 5 years: stood at $53.0 million in 2022, then dropped by 24.53% to $40.0 million in 2023, then soared by 177.5% to $111.0 million in 2024, then soared by 43.24% to $159.0 million in 2025, then sank by 51.57% to $77.0 million in 2026.
- Business Quant data shows BHC's Tax Provisions at $77.0 million in Q1 2026, $159.0 million in Q4 2025, and $37.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 67.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 157.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 676.90 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 43.40 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -423.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 48.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 30.00 Mn |
| 10 | Bausch Health Companies | 1.66 Bn | 1.33 Bn | 2.52 Bn | 77.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 77.00 Mn |
| Dec 31, 2025 | 159.00 Mn |
| Sep 30, 2025 | 37.00 Mn |
| Jun 30, 2025 | 12.00 Mn |
| Mar 31, 2025 | 39.00 Mn |
| Dec 31, 2024 | 111.00 Mn |
| Sep 30, 2024 | 71.00 Mn |
| Jun 30, 2024 | 49.00 Mn |
| Mar 31, 2024 | 8.00 Mn |
| Dec 31, 2023 | 40.00 Mn |
| Sep 30, 2023 | 56.00 Mn |
| Jun 30, 2023 | 52.00 Mn |
| Mar 31, 2023 | 73.00 Mn |
| Dec 31, 2022 | 53.00 Mn |
| Sep 30, 2022 | 36.00 Mn |
| Jun 30, 2022 | 10.00 Mn |
| Mar 31, 2022 | -16.00 Mn |
| Dec 31, 2021 | -51.00 Mn |
| Sep 30, 2021 | 25.00 Mn |
| Jun 30, 2021 | -77.00 Mn |